Primary adrenal insufficiency

Summary

Primary adrenal insufficiency (MONDO:0015128) is a disease and 6 clinical trials. Top therapeutic interventions include hydrocortisone. A subtype of adrenocortical insufficiency — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary adrenal insufficiency
Mondo ID	MONDO:0015128
Orphanet	101958
NCIT	C113172
UMLS	C3887896
MedGen	854614
GARD	0019802
MedDRA	10052381
Is cancer (heuristic)	no

Disease family

This is a subtype of adrenocortical insufficiency. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › adrenal gland disorder › adrenal cortex disorder › adrenocortical insufficiency › primary adrenal insufficiency

Related subtypes (1): secondary adrenal insufficiency

Subtypes (2): chronic primary adrenal insufficiency, acute adrenal insufficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02277587	PHASE4	COMPLETED	Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)
NCT01450930	PHASE2	COMPLETED	Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency
NCT05222152	PHASE2	COMPLETED	Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency
NCT03793114	Not specified	ACTIVE_NOT_RECRUITING	Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison’s Disease
NCT07367425	Not specified	NOT_YET_RECRUITING	Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.
NCT06299020	Not specified	COMPLETED	Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HYDROCORTISONE	4	2